Scientific Glass Instruments BPX5 column (15 m  0.25 mm) using amyl acetate as a lock mass. Elemental analyses were recorded by the elemental analysis service of the London Metropolitan University. Microwave experiments were carried out using a Biotage Initiator 8. Flash column chromatography was carried out using a Presearch Isco Combiflash Companion using Presearch columns or on a Biotage SP4 using Biotage SNAP columns. LCMS t r are quoted to the nearest 0.1 min. LCMS were performed on the following systems: System A: WATERS sunfire C18 column (150 mm × 4.6 mm, 5 µm) using a linear gradient of solvent A (water + 0.01% CF 3 CO 2 H) and solvent B (acetonitrile + 0.01% CF 3 CO 2 H), eluting at a flow rate of 1 mL/min and monitoring at 254 nm: 0% B over 2 min, 0% B to 100% B over 16 min and 100% B over 2 min; System B: Merk Millipore Chromolith Performance RP-18e column (100 mm × 2 mm, 1.6 µm) using a linear gradient of solvent A (water + 0.01% CF 3 CO 2 H) and solvent B (acetonitrile + 0.01% CF 3 CO 2 H), eluting at a flow rate of 1 mL/min and monitoring at 254 nm: 2% B over 2 min, 2% B to 100% B over 8 min and 100% B over 1 min. Sodium metal (345 mg, 15.00 mmol) was added in portions to anhydrous n-PrOH (8 mL) at room temperature using a water bath to dissipate evolved heat. Once all sodium had dissolved, the resulting colourless solution was added drop-wise to a suspension of 4-chloropyridine hydrochloride (750 mg, 5.00 mmol) in n-PrOH (2 mL). The resultant suspension was heated at reflux for 16 h. The mixture was allowed to cool, neutralised by addition of 1 M aq. HCl, and then concentrated in vacuo. The material thus obtained was partitioned between EtOAc (10 mL) and water (10 mL). The phases were separated then the organic phase was washed with brine (10 mL) then dried over MgSO 4 and concentrated in vacuo. The crude material was purified by flash column chromatography on a silica column (24 g). The column was eluted with a gradient of EtOAc:c-hexane which was increased linearly from 40:60 to 80:20 over 12 CVs. The desired fractions were combined and evaporated to yield the product as a colourless oil (637 mg, 93%); R f 0. Chloroacetone (293 μL, 3.56 mmol) was added to a stirred solution of 4-propoxypyridine (630 mg, 3.24 mmol) in THF (15 mL). The resultant mixture was left to stir for 16 h at room temperature then more chloroacetone (293 μL, 3.56 mmol) was added. The mixture was refluxed for 6 h then allowed to cool. Et 2 O (10 mL) was added then the suspension was stirred gently for 16 h. A mixture of compound 4 (84 mg, 0.30 mmol) and K 2 CO 3 (83 mg, 0.60 mmol) in DMF (2 mL) was stirred for 15 minutes. 2-Ethynylpyridine (36 μL, 0.36 mmol) was added then the resultant mixture was heated at 90 °C for 2 h then allowed to cool. The mixture was partitioned between EtOAc (10 mL) and water (10 mL). The organic phase was washed with water (10 mL) and brine (10 mL) then dried over MgSO 4 and evaporated. The crude material was purified by flash column chromatography on a silica column (12 g ). The column was eluted with a gradient of EtOAc:c-hexane which was increased linearly from 20:80 to 50:50 over 12 CVs. The desired fractions were combined and evaporated to yield the product as a pale brown solid (17 mg 
4-Propoxypyridine

1-(2-Oxopropyl)-4-propoxypyridinium chloride (4)
N
1-[7-Propoxy-1-(pyridine-2-yl)indolizin-3-yl]ethanone (2)
), 9.79 (dd, J=7.5, 1.0 Hz, 1 H, C(6)H); 13 C NMR (101 MHz, CDCl 3 )  ppm 10.5 (s, 1 C, C(10) ), 22.3 (s, 1 C, C(9) ), 26.8 (s, 1 C, C(13) ), 69.7 (s, 1 C, C(8) ), 98.5 (s, 1 C, C(3) ), 108.6 (s, 1 C, C(5) ), 112.9 (s, 1 C, C(16) A mixture of compound 4 (84 mg, 0.30 mmol) and K 2 CO 3 (83 mg, 0.60 mmol) in DMF (2 mL) was stirred for 15 minutes. 2-Chloro-6-ethynylpyridine (50 mg, 0.36 mmol) was added then the resultant mixture was heated at 90 °C for 2 h then allowed to cool. The mixture was partitioned between EtOAc (10 mL) and water (10 mL). The organic phase was washed with water (10 mL) and brine (10 mL) then dried over MgSO 4 and evaporated. The crude material was purified by flash column chromatography on a silica column (12 g ). The column was eluted with a gradient of EtOAc:c-hexane which was increased linearly from 20:80 to 50:50 over 12 CVs. The desired fractions were combined and evaporated to yield the product as a beige solid (38 mg, 39%); R f 0. A mixture of compound 4 (84 mg, 0.30 mmol) and K 2 CO 3 (83 mg, 0.60 mmol) in DMF (2 mL) was stirred for 15 minutes. Methyl 2-ethynylisonicotinate (58 mg, 0.36 mmol) was added then the resultant mixture was heated at 90 °C for 2 h then allowed to cool. The mixture was partitioned between EtOAc (10 mL) and water (10 mL). The organic phase was washed with water (10 mL) and brine (10 mL) then dried over MgSO 4 and evaporated. The crude material was purified by flash column chromatography on a silica column (12 g ). The column was eluted with a gradient of EtOAc:c-hexane which was increased linearly from 20:80 to 50:50 over 12 CVs. The desired fractions were combined and evaporated then the resultant material was purified further by flash column chromatography on a C-18 column (13 g A mixture of compound 5 (80 mg, 0.31 mmol), 2-ethynylpyridine (38 μL, 0.37 mmol) and K 2 CO 3 (86 mg, 0.62 mmol) in DMF (2 mL) was heated in a sealed vial for 2 h at 90 °C then allowed to cool. The mixture was then partitioned between water (3 mL) and EtOAc (3 mL). The phases were separated then the organic phase was washed with water (3 mL) and brine (3 mL) then dried over MgSO 4 and evaporated. The crude material was purified by flash column chromatography on a silica column (4 g Cl K 2 CO 3 (323 mg, 2.34 mmol) was added to a solution of compound 5 (300 mg, 1.17 mmol) in DMF (10 mL). The resultant suspension was stirred at room temperature for 15 minutes then 2-ethynylpyridine (189 μL, 1.40 mmol) was added. The mixture was then heated at 90 °C for 2 h then allowed to cool. The solvent was evaporated by N 2 blow-down then the mixture was then partitioned between water (5 mL) and CH 2 Cl 2 (5 mL). The organic phase was collected by passing it through a hydrophobic frit then concentrated by nitrogen blow-down. The crude material was purified by flash column chromatography on a silica column (20 g). The column was eluted with a gradient of EtOAc:c-hexane which was increased linearly from 40:60 to 80:20 over 12 CVs. The desired fractions were combined and evaporated to a yellow solid (180 mg). This material was suspended in MeOH (3 mL) then the supernatant was decanted off with a pipette. This process was repeated (×2) then the residual solid was dried under vacuum to yield the product as a yellow solid (166 mg, 40%) R f 0.45 (EtOAc); mp 215-220 °C; ν max (neat) 3104 (C-H), 2964 (C-H), 2864 (C-H), 1641 (C=O); 1 (18) K 2 CO 3 (47 mg, 0.34 mmol) was added to a solution of compound 5 (80 mg, 0.31 mmol) in DMF (2 mL). The resultant suspension was stirred at room temperature for 10 minutes then 2-ethynyl-6-methylpyridine (40 mg, 0.34 mmol) was added. The mixture was then heated at 90 °C for 2 h then allowed to cool. The mixture was then partitioned between water (3 mL) and CH 2 Cl 2 (3 mL). The organic phase was collected by passing it through a hydrophobic frit then concentrated by nitrogen blow-down. The crude material was purified by flash column chromatography on a silica column (4 g). The column was eluted with a gradient of EtOAc:chexane + 0.1% NEt 3 K 2 CO 3 (47 mg, 0.34 mmol) was added to a solution of compound 5 (80 mg, 0.31 mmol) in DMF (2 mL). The resultant suspension was stirred at room temperature for 10 minutes then 2-ethynyl-6-methoxypyridine (46 mg, 0.34 mmol) was added. The mixture was then heated at 90 °C for 2 h then allowed to cool. The mixture was then partitioned between water (3 mL) and CH 2 Cl 2 (3 mL). The organic phase was collected by passing it through a hydrophobic frit then concentrated by nitrogen blow-down. The crude material was purified by flash column chromatography on a silica column (4 g (12) Cl K 2 CO 3 (108 mg, 0.78 mmol) was added to a solution of compound 5 (100 mg, 0.39 mmol) in DMF (2 mL). The resultant suspension was stirred at room temperature for 15 minutes then 5-chloro-2-ethynylpyridine (59 mg, 0.43 mmol) was added. The mixture was then heated at 90 °C for 2 h then allowed to cool. The solvent was evaporated by N 2 blow-down then the mixture was then partitioned between water (5 mL) and CH 2 Cl 2 (5 mL). The organic phase was collected by passing it through a hydrophobic frit then concentrated by nitrogen blow-down. The crude material was purified by flash column chromatography on a silica column (12 g ). The column was eluted with a gradient of EtOAc:c-hexane + 0.1% NEt 3 which was increased linearly from 40:60 to 80:20 over 12 CVs. The desired fractions were combined and evaporated to an orange solid (39 mg). This material was suspended in MeOH, refluxed, allowed to cool, then filtered to yield the product as a yellow solid (34 mg, 25%); R f 0. (11) K 2 CO 3 (108 mg, 0.78 mmol) was added to a solution of compound 5 (100 mg, 0.39 mmol) in DMF (2 mL). The resultant suspension was stirred at room temperature for 15 minutes then 5-2-ethynyl-5-(trifluoromethyl)pyridine (74 mg, 0.43 mmol) was added. The mixture was then heated at 90 °C for 2 h then allowed to cool. The solvent was evaporated by N 2 blow-down then the mixture was then partitioned between water (5 mL) and CH 2 Cl 2 (5 mL). The organic phase was collected by passing it through a hydrophobic frit then concentrated by nitrogen blow-down. The crude material was purified by flash column chromatography on a silica column (12 g). The column was eluted with a gradient of EtOAc:c-hexane + 0.1% NEt 3 which was increased linearly from 40:60 to 80:20 over 12 CVs. The desired fractions were combined and evaporated to a yellow solid (40 mg). The material thus obtained was purified further by flash column chromatography on a C-18 column (13 g). The column was eluted with a gradient of H 2 O:MeCN (+0.1% CF 3 CO 2 H) which was increased linearly from 95:5 to 5:95 over 20 CVs. The desired fractions were combined and evaporated then partitioned between CH 3 Cl (5 mL) and saturated aq. NaHCO 3 (5 mL). The organic phase was collected by passing through a hydrophobic frit then evaporated to yield the product as a yellow solid (12)), 66.5 (s, 2 C, C(9)+C (11) (14) (12)), 66.5 (s, 2 C, C(9)+C (11)), 99.6 (s, 1 C, C (5) (14) (6)H); 13 (6) (6)H); 13 (6)). A mixture of compound 5 (100 mg, 0.39 mmol) and K 2 CO 3 (108 mg, 0.78 mmol) in DMF (2 mL) was stirred at room temperature for 15 minutes then 2-ethynylpyrimidine (45 mg, 0.43 mmol) was added. The resultant mixture was stirred for 2 h at 90 °C then allowed to cool. The mixture was then partitioned between water (5 mL) and CH 2 Cl 2 (5 mL). The phases were separated using a hydrophobic frit then the organic phase was evaporated. The crude material was purified by flash column chromatography on a silica column (12 g). The column was eluted with a gradient of EtOAc:c-hexane which was increased linearly from 60:40 to 100:0 over 10 CVs. The desired fractions were combined and evaporated to a yellow solid (28 mg K 2 CO 3 (47 mg, 0.34 mmol) was added to a solution of compound 5 (80 mg, 0.31 mmol) in DMF (2 mL). The resultant suspension was stirred at room temperature for 10 minutes then 2-ethynyl-1,3-benzothiazole (55 mg, 0.34 mmol) was added. The mixture was then heated at 90 °C for 2 h then allowed to cool. The mixture was then partitioned between water (3 mL) and CH 2 Cl 2 (3 mL). The organic phase was collected by passing it through a hydrophobic frit then concentrated by nitrogen blow-down. The crude material was purified by flash column chromatography on a silica column (4 g). The column was eluted with a gradient of EtOAc:chexane + 0.1% NEt 3 which was increased linearly from 40:60 to 80:20 over 20 CVs. The desired fractions were combined and evaporated. The resultant solid was suspended in MeOH then filtered to yield the product as an orange solid (14 (12)), 66.4 (s, 2 C, C(9)+C (11) N K 2 CO 3 (108 mg, 0.78 mmol) was added to a solution of compound 5 (100 mg, 0.39 mmol) in DMF (2 mL). The resultant suspension was stirred at room temperature for 15 minutes then 5-ethynylimidazo [1,2a] pyridine (61 mg, 0.43 mmol) was added. The mixture was then heated at 90 °C for 2 h then allowed to cool. The solvent was evaporated by N 2 blow-down then the mixture was then partitioned between water (5 mL) and CH 2 Cl 2 (5 mL). The organic phase was collected by passing it through a hydrophobic frit then concentrated by nitrogen blow-down. The crude material was purified by flash column chromatography on a silica column (12 g ). The column was eluted with a gradient of EtOAc:MeOH:NEt 3 which was increased linearly from 99:1:0.1 to 90:10:1 over 12 CVs. The desired fractions were combined and evaporated to a cream solid (32 mg). The material thus obtained was purified further by flash column chromatography on a C-18 column (4.3 g). The column was eluted with a gradient of H 2 O:MeCN (+0.1% CF 3 CO 2 H) which was increased linearly from 95:5 to 5:95 over 12 CVs. The desired fractions were combined and evaporated then partitioned between CH 2 Cl 2 (2 mL) and saturated aq. NaHCO 3 (2 mL). The organic phase was collected by passing through a hydrophobic frit then evaporated to yield the product as a yellow solid ( The resultant suspension was stirred at room temperature for 15 minutes then methyl 2-ethynylisonicotinate (151 mg, 0.93 mmol) was added. The mixture was then heated at 90 °C for 2 h then allowed to cool. The solvent was evaporated by N 2 blow-down then the mixture was then partitioned between water (5 mL) and CH 2 Cl 2 (5 mL). The organic phase was collected by passing it through a hydrophobic frit then concentrated by nitrogen blow-down. The crude material was purified by flash column chromatography on a silica column (12 g ). The column was eluted with a gradient of EtOAc:c-hexane which was increased linearly from 60:40 to 100:0 over 12 CVs. The desired fractions were combined and evaporated to an orange solid (127 mg). This material was suspended in MeOH (3 mL) then the supernatant was decanted off with a pipette. This process was repeated (×2) then the residual solid was dried under vacuum to yield the product as a yellow solid (96 mg, 32%) R f 0. C, C(8)+C(12)), 65.8 (s, 2 C, C(9)+C(11)), 98.8 (s, 1 C, C(5)), 106.4 (s, 1 C, C(3)), 110.6 (s, 1 C, C(16)),  118.1 (s, 1 C, C(21)), 118.7 (s, 1 C, C(23)), 120.8 (s, 1 C, C(13)), 124.4 (s, 1 C, C(17)), 128.7 (s, 1 C, C(2)), 138.9  (s, 1 C, C(22)), 139.7 (s, 1 C, C(6)), 148.6 (s, 1 C, C(4)), 149.7 (s, 1 C, C(20)), 155.5 (s, 1 C, C(18)), 166.8 (s, 1 C,  C(24)), 185.0 (s, 1 C, C(14) (12)), 53.9 (s, 2 C, C(9)+C (11) K 2 CO 3 (138 mg, 1.00 mmol) was added to a solution of compound 6 (135 mg, 0.50 mmol) in DMF (5 mL). The resultant suspension was stirred at room temperature for 15 minutes then 5-ethynylimidazo [1,2a] pyridine (78 mg, 0.55 mmol) was added. The mixture was then heated at 90 °C for 4 h, allowed to cool, then partitioned between water (10 mL) and CHCl 3 (10 mL). The organic phase was collected by passing it through a hydrophobic frit then concentrated by nitrogen blow-down. The crude material was purified by flash column chromatography on a silica column (24 g). The column was eluted with a gradient of CH 2 Cl 2 :-MeOH:NH 4 OH which was increased linearly from 99:1:0.1 to 95:5:0.5 over 10 CVs. The desired fractions were combined and evaporated to a red gum (39 mg). The material thus obtained was purified further by flash column chromatography on a C-18 column (13 g). The column was eluted with a gradient of H 2 O:MeCN (+0.1% CF 3 CO 2 H) which was increased linearly from 95:5 to 5:95 over 20 CVs. The desired fractions were combined and evaporated then partitioned between CHCl 3 (5 mL) and saturated aq. NaHCO 3 (5 mL). The organic phase was collected by passing through a hydrophobic frit then evaporated to a red gum (19 mg). The material thus obtained was re-dissolved in the minimum of CHCl 3 A suspension of K 2 CO 3 (40 mg, 0.29 mmol) was added to a solution of compound 7 (93 mg, 0.26 mmol) in DMF (2 mL). The resultant suspension was stirred at room temperature for 10 minutes then 2-ethynylpyridine (29 μL, 0.29 mmol) was added. The mixture was then heated at 90 °C for 2 h then allowed to cool. The mixture was then partitioned between water (5 mL) and CH 2 Cl 2 (5 mL). The organic phase was collected by passing it through a hydrophobic frit then evaporated. The crude material was purified by flash column chromatography on a silica column (4 g). The column was eluted with a gradient of EtOAc:c-hexane + 0.1% NEt 3 (4) 4-[3-acetyl-1-(imidazo[1,2-a]pyridin-5-yl) (12)), 58.8 (s, 1 C, C (13)), 65.5 (s, 2 C, C(9)+C (11) (6) (12)), 53.8 (s, 2 C, C(9)+C (11)), 62.7 (s, 1 C, C (13)), 107.7 (s, 2 C, C(3)+C (5)), 143.6 (s, 2 C, C(2)+C (6) 1-Chlorohexan-2-one (228 mg, 1.69 mmol) was added drop-wise to a stirred solution of 1-methyl-4-(pyridin-4-yl)piperazine (300 mg, 1.69 mmol) in THF (10 mL). The resultant mixture was left to stir at room temperature for 18 h. The resultant suspension was filtered then the filtrate was left to stand for 24 h, resulting in further precipitation. The precipitate was filtered, to yield the product as a beige solid (427 mg, 44%); mp 210-214 °C; ν max (neat) 3036 (C-H), 2948 (C-H), 2869 (C-H), 2810 (C-H), 2778 (C-H), 1727 (C=O); 1 Methylpiperazin-1-yl)-1-(3,3,3 (12)), 53.6 (s, 2 C, C(9)+C (11)), 58.7 (s, 1 C, C (13) (6) [1,2a] pyridine (63 mg, 0.44 mmol) was added. The mixture was then heated at 90 °C for 3 h then allowed to cool. The resultant mixture was partitioned between water (5 mL) and EtOAc (5 mL). The phases were separated then the aqueous phase was extracted with more EtOAc (2×5 mL). The combined organic phases were washed with water (2×5mL) and brine (5 mL) then dried over MgSO 4 and evaporated. The crude material was preadsorbed onto silica then purified by flash column chromatography on a silica column (12 g ). The column was eluted with a gradient of CH 2 Cl 2 :MeOH:NH 4 OH which was increased linearly from 99:1:0.1 to 95:5:0.5 over 12 CVs. The desired fractions were combined and evaporated to a beige solid (56 mg). The material thus obtained was purified further by flash column chromatography on a C-18 column (13 g). The column was eluted with a gradient of H 2 O:MeCN (+0.1% CF 3 CO 2 H) which was increased linearly from 95:5 to 5:95 over 20 CVs. The desired fractions were combined and evaporated then partitioned between CHCl 3 (5 mL) and saturated aq. NaHCO 3 (5 mL). The organic phase was collected by passing through a hydrophobic frit then evaporated to yield the product as a yellow gum (5 mg, 3.3%); R f 0.55 (CH 2 Cl 2 :MeOH:NH 4 (5)), 96.5 (s, 1 C, C(14) ), 105.7 (s, 1 C, C (7)), 106.2 (s, 1 C, C(12) ), 111.6 (s, 1 C, C(27) ), 113.1 (s, 1 C, C(22) ), 115.6 (s, 1 C, C(20) 121.1 (s, 1 C, C(9) ), 123.6 (s, 1 C, C (8) [1,2a] pyridine (63 mg, 0.44 mmol) was added. The mixture was then heated at 90 °C for 3 h then allowed to cool. The resultant mixture was partitioned between water (5 mL) and EtOAc (5 mL). The phases were separated then the aqueous phase was extracted with more EtOAc (2×5 mL). The combined organic phases were washed with water (2×5mL) and brine (5 mL) then dried over MgSO 4 and evaporated. The crude material was purified by flash column chromatography on a silica column (12 g ). The column was eluted with a gradient of CH 2 Cl 2 :MeOH:NH 4 The resultant suspension was stirred at room temperature for 15 minutes then 5-ethynylimidazo [1,2a] pyridine (63 mg, 0.44 mmol) was added. The mixture was then heated at 90 °C for 3 h then allowed to cool and stirred at room temperature for 16 h. The resultant mixture was partitioned between water (5 mL) and EtOAc (5 mL). The phases were separated then the aqueous phase was extracted with more EtOAc (2×5 mL). The combined organic phases were washed with water (2×5mL) and brine (5 mL) then dried over MgSO 4 and evaporated. The crude material was purified by flash column chromatography on a silica column (12 g). The column was eluted with a gradient of CH 2 Cl 2 :MeOH:NH 4 (13) (6) 
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1-[1-(6-Chloropyridin-2-yl)-7-propoxyindolizin-3-yl]ethanone (16)
N), 99.3 (s, 1 C, C(5)), 106.0 (s, 1 C, C(3)), 111.3 (s, 1 C, C(16)), 120.4 (s, 1 C, C(23)), 121.2 (s, 1 C, C(13)), 123.6 (s, 1 C, C(17)), 127.3 (s, 1 C, C(21)), 129.7 (s, 1 C, C(2)), 136.0 (s, 1 C, C(22)), 139.4 (s, 1 C, C(6)), 147.7 (s, 1 C, C(20)), 148.9 (s, 1 C, C(4)), 152.9 (s, 1 C, C(18)),
1-[1-(3-Fluoropyridin-2-yl)-7-(morpholin-4-yl)indolizin-3-yl]ethanone (24)
N), 99.7 (s, 1 C, C(5)), 106.1 (s, 1 C, C(3)), 106.9 (d, J=5.5 Hz, 1 C, C(3)), 120.1 (d, J=4.0 Hz, 1 C, C(21)), 121.4 (d, J=3.0 Hz, 1 C, C(13)), 122.9 (d, J=20.0 Hz, 1 C, C(20)), 126.0 (d, J=15.0 Hz, 1 C, C(17)), 129.7 (s, 1 C, C(2)), 140.1 (s, 1 C, C(6)), 143.7 (d, J=10.5 Hz, 1 C, C(18)), 144.5 (d, J=5.0 Hz, 1 C, C(22)), 148.8 (s, 1 C, C(4)), 156.3 (d, J=259.0 Hz, 1 C, C(19)), 185.5 (s, 1 C, C
1-[1-(3-Fluoro-5-methylpyridin-2-yl)-7-(morpholin-4-yl)indolizin-3-yl]ethanone (25)
N), 106.1 (s, 1 C, C(3)), 107.1 (d, J=6.5 Hz, 1 C, C(16)), 121.3 (d, J=3.0 Hz, 1 C, C(13)), 123.6 (d, J=20.0 Hz, 1 C, C(20)), 125.7 (d, J=13.5 Hz, 1 C, C(17)), 129.6 (s, 1 C, C(2)), 130.7 (d, J=4.0 Hz, 1 C, C(2)), 139.8 (s, 1 C, C(6)), 140.7 (d, J=11.0 Hz, 1 C, C(18)), 144.8 (d, J=4.0 Hz, 1 C, C(22)), 148.6 (s, 1 C, C(4)), 156.1 (d, J=259.0 Hz, 1 C, C(19)), 185.4 (s, 1 C, C
2-[(Tripropan-2-ylsilyl)ethynyl]pyrimidine
C NMR (101 MHz, CDCl 3 )  ppm 11.2 (s, 3 C, (3×TIPS CH)), 18.6 (s, 6C (6×TIPS CH 3 ) 91.2 (s, 1 C, C(8)), 104.7 (s, 1 C, C(7)), 119.9 (s, 1 C, C(5)), 152.7 (s, 1 C, C(2)), 157.2 (s, 2 C, C(4)+C
2-Ethynylpyrimidine 1
C NMR (101 MHz, CDCl 3 )  ppm 75.8 (s, 1 C, C(8)), 81.7 (s, 1 C, C(7)), 120.4 (s, 1 C, C(5)), 152.1 (s, 1 C, C(2)), 157.2 (s, 2 C, C(4)+C
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1-[7-(Morpholin-4-yl)-1-(pyrimidin-2-yl)indolizin-3-yl]ethanone (26)
N)  ppm 26.8 (s, 1 C, C(15)), 47.5 (s, 2 C, C(8)+C(12)), 66.5 (s, 2 C, C(9)+C(11)), 99.9 (s, 1 C, C(5)), 105.7 (s, 1 C, C(3)), 111.2 (s, 1 C, C(16)), 116.1 (s, 1 C, C(21)), 121.7 (s, 1 C, C(13)), 126.2 (s, 1 C, C(17)), 130.0 (s, 1 C, C(2)), 140.6 (s, 1 C, C(6)), 149.1 (s, 1 C, C(4)),
1-[1-(1,3-Benzothiazol-2-yl)-7-(morpholin-4-yl)indolizin-3-yl]ethanone (27)
1-Methyl-4-(pyridin-4-yl)piperazine
4-[4-(tert-Butoxycarbonyl)piperazin-1-yl]-1-(2-oxopropyl)pyridinium chloride (7)
1-[7-(Piperazin-1-yl)-1-(pyridin-2-yl)indolizin-3-yl]ethanone dihydrochloride (29)
tert-Butyl
4-(Morpholin-4-yl)-1-(3,3,3-trifluoro-2,2-dihydroxypropyl)pyridinium bromide (9)
4-(4-Methylpiperazin-1-yl)-1-(2-oxobutyl)pyridinium bromide (10)
1-(2-Cyclopropyl-2-oxoethyl)-4-(4-methylpiperazin-1-yl)pyridinium bromide (12)
4-(4-
Protein Expression and Purification
cDNA encoding reported human bromodomains were cloned, expressed and purified as previously described. 5, 6 Differential Scanning Fluorimetry (DSF)
Thermal melting experiments were carried out using an Mx3005p Real Time PCR machine (Stratagene). Proteins were buffered in 10 mM HEPES pH 7.5, 500 mM NaCl and assayed in a 96-well plate at a final concentration of 2 μM in 20 μL volume. Compounds were added at a final concentration of 10 μM. SYPRO Orange (Molecular Probes) was used as a fluorescence probe at a dilution of 1:1000. Excitation and emission
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filters for the SYPRO-Orange dye were set to 465 nm and 590 nm, respectively. The temperature was raised with a step of 3 °C per minute from 25 °C to 96 °C and fluorescence readings were taken at each interval. Data was analysed as previously described. 7
Isothermal Titration Calorimetry (ITC)
Experiments were carried out on a VP-ITC microcalorimeter (MicroCal™). All experiments were performed at 15 °C in 20 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM TCEP. BRD9 protein solution was buffer exchanged by gel filtration or dialysis into the ITC buffer. The titrations were conducted using an initial injection of 2 µl followed by 34 identical injections of 8 µl. The dilution heats were measured on separate experiments and were subtracted from the titration data. Thermodynamic parameters were calculated using ∆G = ∆H -T∆S = -RTlnK B , where ∆G, ∆H and ∆S are the changes in free energy, enthalpy and entropy of binding respectively. In all cases a single binding site model was employed.
Crystallization
BRD9 construct (Uniprot identifier as BRD9 HUMAN Q9H8M2-1 fragment 14-134) was used for all crystallographic studies. Aliquots of the purified proteins were set up for crystallization using a mosquito® crystallization robot (TTP Labtech). Coarse screens were typically setup onto Greiner 3-well plates using three different drop ratios of precipitant to protein per condition (200 + 100 nL, 150 + 150 nL and 100 + 200 nL). All crystallizations were carried out using the sitting drop vapour diffusion method at 4°C. BRD9 crystals with compound 28 (2 mM final concentration) were obtained by mixing 200 nL of the protein (14 mg/ml) and 100 nL crystallization buffer (0.2 M NaNO3, 0.1 M BTProp pH 6.5, 20% PEG 3350, 10% EtGly).
Fluorescence Recovery After Photobleaching (FRAP) Assay
FRAP studies were performed using U2OS cells expressing a full-length BRD9 protein fused with an Nterminal eGFP as previously described. 8 In short, six hours after transfection 2.5 μM SAHA and compound 28 were added. Imaging was carried out 24 hours after transfection.
Data Collection and Structure Solution
Crystals were cryo-protected using the well solution supplemented with additional 15% ethylene glycol and were flash frozen in liquid nitrogen. Data were collected at Diamond Light Source beamline I04-1 at a wavelength of 0.92 Å. Indexing and integration was carried out using XDS 9 and scaling was performed with AIMLESS. 10 Initial phases were calculated by molecular replacement with PHASER 11 using an ensemble of known bromodomain models (PDB IDs 2OSS, 2OUO, 2GRC, 2OO1, 3DAI, 3D7C, 3DWY, 3G0L). Unique and initial solutions were improved in a total of 50 cycles of automated protein chain tracing starting from existing model and computed using ARP/wARP. Further manual building with COOT and refinement against maximum likelihood target using REFMAC5. Thermal motions were analyzed using TLSMD 12 and hydrogen atoms were included in late refinement cycles. PRODRG 13 was used to generate compound coordinates and cif files. All model validations were carried out using MolProbity 14 Data collection and refinement statistics are compiled in Supplemental Table 1 . The models and structure factors have been deposited into the pdb.
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